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Abstract
Antiretroviral (ARV) adherence has largely been considered from the perspective of an individual’s behavior
with less attention given to potential structural causes for lapses in treatment, such as the cost of medications
and care. HIV medication expense is typically covered by third party payers. However, private insurance
premiums and deductibles may rise, or policies terminated such as with a change in employment. Likewise, a
patient’s eligibility for publicly funded coverage like state AIDS Drug Assistance Programs (ADAP) or
Medicaid can also be lost. We conducted a one-time survey of a sample of 300 patients receiving HIV care at a
single large academic center in the south of United States to examine lapses in HIV therapy due to financial
reasons. We found that during the prior year, financial issues including medication cost or coverage led to a
lapse in ARVs in 10% (n = 31) of participants. However, of the 42% (n = 125) participants who had been
enrolled in ADAP at any time during the prior year, 21% (n = 26) reported an ARV lapse due to problems with
ADAP or medication cost. Respondents cited ADAP’s required semi-annual renewal process and other ad-
ministrative issues as the cause of ARV lapses. The median duration of missed ARVs was 2 weeks (range of
<1–23 weeks). Non-HIV medication and transportation to and from clinic costs were also identified as financial
burdens to care by respondents. In conclusion, although conducted at a single medical center and one state, this
study suggests that a significant minority of HIV-infected patients encounter financial barriers to ARV access,
and this is paradoxically more common among those enrolled in the state ADAP. Streamlining, supporting, and
simplifying ADAP renewal procedures will likely reduce lapses in ARV adherence and persistence.
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Introduction
Uninterrupted adherence to antiretroviral (ARV)treatment is essential to successful long-term manage-
ment of HIV infection. Continuous ARV therapy suppresses
viral replication, protects CD4+ lymphocytes count, prevents
disease progression, reduces the potential for drug resistance,
and greatly diminishes the risk of HIV transmission.1–6 While
a considerable amount of research examining the medication-
taking behaviors of people living with HIV infection has been
conducted, little work has been done to explore the effect of
structural factors, such as the processes for procuring and
paying for ARVs, as a barrier to continuous access to HIV
therapy.
The annual cost of ARV medications for the treatment of
HIV can easily exceed $30,000 without medication insurance
coverage or other assistance.1 Private insurance will typically
pay for a large proportion of the cost of HIV therapy, but
policies vary considerably in the extent of coverage and most
policy holders remain responsible for deductibles or co-
payments. Publically funded ARV coverage, particularly the
largely state funded AIDS Drug Assistance Programs
(ADAP), provide ARVs, as well as many other medications
for comorbid conditions, at no cost to lower income patients
who meet financial criteria established by each state. Ap-
proximately, a quarter of all persons in HIV care in the United
States are enrolled in ADAP, including over 7400 people in
North Carolina.7 In addition, pharmaceutical companies have
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programs that provide co-payment assistance for those with
private insurance or directly provide medication at no cost to
qualifying individuals.
In this study, we sought to better understand the extent that
people living with HIV fall through this safety net of medi-
cation coverage and struggle to pay for their HIV medica-
tions. We surveyed a sample of adult patients receiving HIV
care at a large academic outpatient clinic in North Carolina to
determine the extent that financial barriers, including medi-
cation costs and changes in health insurance coverage, result
in lapses in ARV therapy. In addition, we explored the most
common specific financial barriers encountered by HIV-
infected patients when accessing their HIV and non-HIV
medications and healthcare.
Methods
Study setting and population
Participants were recruited from the University of North
Carolina at Chapel Hill (UNC) Infectious Diseases (ID)
Clinic. This clinic serves *1800 patients with HIV infection
across North Carolina. As described previously, *30% of
clinic patients have private health insurance, 50% public/
governmental insurance, and 20% are uninsured.8 To qualify
for ADAP in North Carolina, recipients must have a gross
income at or below 300% of the Federal Poverty Level.9 The
state ADAP requires beneficiaries to renew their ADAP ap-
plication every 6 months to provide evidence of continued
qualification for the program.
Outpatients attending clinic visits and determined to be
eligible were randomly selected for screening and those who
consented were enrolled. Inclusion criteria included con-
firmed diagnosis of HIV infection, age 18 years and greater,
prescribed ARVs in the past 12 months, and fluency in En-
glish. Individuals were excluded if they presented to the UNC
ID Clinic for their first appointment as a new patient. This
study was approved by the UNC Institutional Review Board.
Study procedures
Research personnel interviewed and consented patients at
their routinely scheduled ID Clinic visit. Patient interviews
were purposefully conducted on each weekday and during
morning and afternoon clinic hours so that patients from
all providers would be well represented in our sample.
The questionnaire was administered via Computer Assisted
Personal Interviewing and included a mix of open- and
closed-ended questions. Qualtrics Survey Software was used
to directly record interview responses. The survey included
questions regarding participant demographics and socioeco-
nomic status that were adapted from the 2014 Centers for
Disease Control and Prevention Behavioral Risk Factor
Surveillance System Questionnaire.10 To determine lapses in
ARV therapy due to financial barriers all participants were
asked, ‘‘Was there ever a time in the past 12 months when
you did not take any of your HIV medications, even for one
day, because of cost?’’ In addition, survey items probed the
estimated costs of ARVs and non-HIV medications, duration
of longest lapse in ARV therapy due to financial reasons,
financial barriers to accessing medicines and healthcare,
health insurance status, ADAP enrollment status, and access
to non-HIV primary care. A question regarding transportation
as a barrier to receiving HIV care was added subsequent to
the enrollment of the first 30 participants. The complete
survey can be found in Supplemental Materials. Participants
received $5 in cash at the conclusion of the interview.
Data analysis
Descriptive statistics were used to summarize collected
data. All data were analyzed using Microsoft Excel and
Qualtrics Survey Software.
Results
Participant recruitment and characteristics
During the months of March to May 2015, all patients
(n = 1184) with an appointment at the UNC ID Clinic were
screened for inclusion. Of these, 706 patients were deter-
mined to meet the study eligibility criteria and presented for
their appointment. A random sample of 300 of these patients
distributed across each weekday and the morning and after-
noon clinic sessions were enrolled (Fig. 1).
Participants were mostly male and middle aged; approxi-
mately two-thirds self-identified as African American or
black (Table 1). The median annual income stratum was
$10,000–15,000 with an average household size of two and
25% of those interviewed were working full time, with most
of the remainder receiving disability benefits or unemployed.
During the prior year, 42% (n = 125) had been enrolled in
ADAP and 35% (n = 106) reported they received the ARVs
through ADAP. Other forms of ARV coverage reported
FIG. 1. Study participant selection and recruitment. ID,
Infectious Diseases; UNC, University of North Carolina at
Chapel Hill.
included private insurance plans and Medicaid. Twenty
percent reported not having any health insurance. During the
prior year, 66% experienced no changes in their health in-
surance coverage, 5% lost their health insurance coverage,
5% gained health insurance coverage, and 4% changed health
insurance plans. Approximately two-thirds received ARVs at
no cost and for almost a quarter the average monthly out of
pocket cost for ARVs was <$25. A co-pay card provided by
an ARV pharmaceutical company was used by 17%.
Financial barriers to continuous ARV therapy
During the prior year, 10% (n = 31) of participants reported
at least one lapse in ARV medication of a day or longer due to
financial reasons, including the cost of medications or prob-
lems with medication coverage (e.g., ADAP). Overall, 11%
of the participants indicated that their ARVs are ‘‘not at all’’
affordable (Fig. 2).
Among the 125 participants enrolled in ADAP at any time
during the prior year, 21% (n = 26) reported missing at least
1 day of their ARVs due to problems with ADAP or due to
medication cost, with a median 2-week duration of missed
ARVs (range of <1–23 weeks). For the 22 patients citing
ADAP problems as the cause of their ARV lapse, 41% (n = 9)
stated their ADAP coverage was not renewed because they
missed the every 6-month ADAP renewal deadline. Reasons
for missing the ADAP deadline included the following: not
being aware of the requirement or forgetting to reapply for
ADAP coverage every 6 months, difficulty providing the
information needed to renew coverage, lack of transportation
to the clinic to renew their application, administrative diffi-
culties that led to lapses in ARV therapy such as the ADAP
renewal process taking longer than anticipated, lost paper-
work after submission, and delays in ADAP pharmacy
mailing of ARVs. Two participants also reported they be-
came employed and briefly earned too much to qualify for
ADAP coverage.
In contrast, for the 175 not enrolled in ADAP, 3% (n = 5)
reported a lapse due strictly to the cost of their ARV. For
these patients, the median duration of the longest lapse in
ARV treatment was 1 week, with a range of 1–4 weeks. These
individuals cited the following reasons for being unable to
afford their ARV medications: no health insurance to pay for
HIV medicines, loss of the health insurance that was paying
for ARVs, a research study providing ARVs ended, problems
with pharmacy/prescription renewal, the co-pay for their
ARV medication increased, and unable to afford the co-pay.
Financial barriers to HIV care
Among all participants, 4% (n = 12) reported they were
unable to attend an HIV clinic visit at least once in the pre-
vious 12 months due to cost. Half (n = 147) of the participants
reported no clinic co-pay and for those with a co-pay the
median self-reported amount was $40 (range of $0–450).
Participants also cited transportation costs as a barrier to re-
ceiving HIV care, 27% (n = 73) of the 270 participants asked
about transportation reporting the cost of transportation
prevented them from accessing their HIV care and/or medi-
cations at least once in the previous 12 months.
Overall, 21% of participants perceived their HIV-related
medication and healthcare out of pocket costs to be ‘‘not
at all’’ or ‘‘not very’’ affordable, while 29% indicated these
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ADAP, AIDS Drug Assistance Programs.
were ‘‘somewhat’’ affordable, and 45% responded these were
‘‘very’’ affordable.
Financial barriers to non-HIV medications and care
Of the 62% (n = 185) of participants who reported cur-
rently taking medicines other than ARVs at the time of the
interview, 36% (n = 67) reported missing >1 day of their non-
HIV medications at least once in the past year exclusively due
to the cost of the medications (Fig. 2). The median duration of
the longest lapse in non-HIV treatment was 3–4 weeks, with a
range of <1 week to >12 months.
The median monthly cost for non-HIV medications among
the cohort was $1–25, but ranged from $0 to $1000. Nearly
half (46%) of the participants taking non-HIV medications
obtained these at no cost and an additional 30% paid <$25 out
of pocket each month for these medications.
Among those who reported being ADAP recipients who were
prescribed non-HIV medications (n = 111), 32% (n = 35) had a
lapse in these medications due to cost. For those not enrolled in
ADAP and prescribed non-HIV medications (n = 74), 43%
(n = 32) had a lapse in these medications due to cost.
An inability to see a healthcare provider at least once in the
previous 12 months for their non-HIV healthcare due to cost
was reported by 22% (n = 66); and 180 (60%) of participants
did not have a primary care provider for non-HIV-related
healthcare. Participants also cited transportation costs as a
barrier to receiving non-HIV care, with 22% (n = 59) of the
270 asked about transportation reporting the cost of trans-
portation prevented them from accessing their non-HIV care
and/or medications at least once in the previous 12 months.
Overall, 27% of participants perceived their non-HIV-
related medication and healthcare out of pocket costs to be ‘‘not
at all’’ or ‘‘not very’’ affordable, while 32% indicated these
were ‘‘somewhat’’ affordable, and 31% responded these were
‘‘very’’ affordable. Over half (54%) of the participants reported
having outstanding healthcare bills for their combined HIV-
and non-HIV-related medicines and healthcare, including bills
for medical, dental, and/or physical therapy costs.
Discussion
HIV medication adherence has been examined largely in
terms of individual medication-taking behaviors, with less
attention paid to structural reasons for treatment lapses, such
as financial barriers to ARVs and HIV care.11–14 We found
that cost and access to treatment and care of HIV are barriers
to ARV persistence for many patients, despite ADAP, med-
ication insurance, and pharmaceutical company support
programs. One in 10 people living with HIV surveyed ex-
perienced at least a single lapse in HIV therapy during the
preceding year due to cost and one in five stated that they
could not afford their HIV care. The lapses in ARV therapy
reported by both those with and without ADAP support were
not trivial. Treatment interruptions for the periods reported
are sufficient for viral rebound. Resurgent viremia can have a
number of consequences including an increase in transmis-
sion potential, and a small but real risk of drug resistance and
CD4+ cell depletion.
The risk of a break in taking HIV medications was para-
doxically found to be substantially higher among those en-
rolled in the state ADAP, which provides ARVs at no cost to
those who qualify based on income, compared to those not
enrolled in this program. Of the 10% of the cohort who re-
ported a lapse in ARV therapy, 84% were ADAP recipients
(Fig. 3). We expected those enrolled in ADAP to have stable
access to HIV medications compared to the uninsured and
those with private insurance coverage, who are typically
subjected to co-pays, deductibles, and changes in policy
benefits; however, >20% of ADAP recipients experienced at
least one lapse in ARV supply during the prior year; half had
a break in treatment for two or more weeks.
FIG. 2. Reported financial barriers to HIV and Non-HIV care. *Of 270 asked about transportation barriers. **Of 185
participants reporting being prescribed non-HIV medications.
Data from the National Alliance of State and Territorial
AIDS Directors (NASTAD) echo these findings.15 Of the
258,469 clients enrolled in ADAP nationwide in fiscal year
2013, 18% had not recertified twice during the prior 12-
month period. Other studies have also probed for barriers to
HIV care and therapy in the United States and several find
that HIV-infected individuals may delay or discontinue an-
tiretroviral therapy (ART) despite the support provided by
safety-net programs.16 In Washington state, where access to
ART is near universal, Dombrowski et al. found that 50% of
patients enrolled in a public health HIV linkage program in
Seattle reported absence of insurance as a barrier to care—
and of those discontinuing ART, 31% stated that they could
not afford HIV medications and 28% said they could not get
access to ART for reasons other than cost.16 Ludema et al.
examining viral suppression and insurance status and type
among 1481 HIV-infected participants in the Women’s In-
teragency HIV Study from 2006 to 2009 observed viral
suppression to be least likely among women without insur-
ance and also those receiving Medicaid alone.17 In that study,
ADAP alone or in addition to public insurance increased the
likelihood of viral suppression—highlighting the overall
benefits of ADAP. Non-ADAP Ryan White HIV/AIDS
Program services have also been found to be associated
with positive clinical outcomes, including viral suppres-
sion, particularly among patients living in poverty, who are
often individuals demonstrated to be at greater risk for
under-treatment of HIV infection including younger pa-
tients, women, and African Americans.18–20
Therefore, while ADAP has been highly successful in
providing crucial access to HIV therapy and services for
thousands of people living with HIV infection, and has
been credited with raising life expectancy and reducing
racial and ethnic differences in treatment outcomes,21 it
and other programs that provide ART at no cost do not
completely eliminate financial barriers to HIV therapy. In
the case of ADAP, aspects of the program, such as the
every 6-month recertification, may lead to interruptions in
ARV therapy for a substantial proportion of patients. A
qualitative study of ADAP recipients in Birmingham,
Alabama similarly found that the complexities of ADAP
recertification act as a barrier to ARV continuity—a
finding that transcended race and gender.22 As people
living with HIV infection have a relatively high prevalence
of comorbid medical and mental health conditions, and
may also have limited healthcare literacy, they may be
particularly challenged in their ability to comply with the
requirements for continued participation in programs that
provide for ART and HIV care.
In addition to identifying financial barriers to HIV-related
healthcare, participants taking medicines for non-HIV con-
ditions also reported financial barriers to healthcare and
medicines for their non-HIV conditions. In comparison to
the 21% of the study participants who stated that their HIV
healthcare and medicines were not very affordable or not at
all affordable, 27% of the participants felt that their non-HIV
healthcare and medicines were either not very affordable or
not at all affordable. Lapses in non-HIV medicines due to
cost were reported by 14% of the respondents, double the
proportion reporting a financially motivated break in ARV
treatment. Further, a quarter reported not seeing their
healthcare provider for non-HIV healthcare due to cost,
suggesting that access to non-HIV healthcare remains diffi-
cult for those with limited financial means. Transportation to
medical visits was also found to be a problem for many pa-
tients living with HIV infection and was a barrier to accessing
both HIV and non-HIV-related care during the prior 12
months.
Overall, our results reveal a subset of HIV-infected pa-
tients who are unable to easily obtain necessary therapy and
healthcare due to cost. It is notable that this study was con-
ducted after the passage and enactment in 2010 of the Patient
Protection and Affordable Care Act (ACA) which, in general,
expanded health insurance and medication coverage. How-
ever, North Carolina, like the vast majority of states in the US
South, opted to not expand Medicaid under the ACA. It has
been estimated that Medicaid expansion in North Carolina
would result in as much as an additional 400,000–500,000
people becoming insured.23 The income levels reported
by the participants indicate many would be eligible for
Medicaid, were North Carolina to expand this public health
care program.
There are a number of important limitations to this study.
Foremost, this research was conducted at a single academic
center in one Southern state in the United States. The bar-
riers to treatment and care can be expected to vary by clinic
setting and locale. Selection bias could have been intro-
duced as only patients who attended clinic visits were in-
cluded and interviewed. In addition, non-English speaking
patients, who make up <5% of the clinic population, were
excluded and these individuals may have very different
experiences paying for and accessing HIV medications and
care than other patients attending the clinic. Additionally,
our research was conducted at a single hospital-based out-
patient clinic located within a large academic medical
center. By selecting participants presenting to an ID Clinic
at a major academic medical center, we likely under-
estimated the true prevalence of financial barriers that exist
in other parts of North Carolina or among patients who miss
visits or are not able present to a healthcare facility, possibly
due to unsurmountable barriers to care. Further, respondents
were asked about medication coverage during the prior 12
months. Those who enrolled in ADAP for <6 months before
the interview would not have had an opportunity to go
through the ADAP recertification process. Therefore, our
estimate of the impact of ADAP recertification on ARV
persistence may be conservative. Other limitations include a
FIG. 3. Lapses in ART among overall cohort (n = 300)
and proportion of those experiencing ART lapse who ADAP
receipients. ADAP, AIDS Drug Assistance Programs; ART,
antiretroviral therapy.
reliance on patient self-report. While the study survey in-
cluded items that have been used in other surveys of HIV-
infected patients, participants may not have always been
willing and able to provide accurate answers to questions
regarding financial matters.
In summary, despite the overall benefit of programs de-
signed to provide HIV treatment that is affordable, some
patients living with HIV infection still report financial bar-
riers to continuous access to these medications. Many patients
also report struggling to pay for HIV-related and non-HIV-
related medical care. While ADAP has been successful in
bringing people with HIV infection into care by providing
them with HIV-related medicines and healthcare at no or little
cost, our findings show that for some, the administrative re-
quirements of the program may act as an obstacle to ARV
access and adherence. These findings highlight the role that
structural barriers can play in preventing individuals with HIV
infection from maintaining optimal adherence to their ARV
regimens and accessing necessary HIV-related healthcare.
There is a need for corrective actions to address the structural
issues within the healthcare system that act as obstacles to
motivated individuals seeking HIV care. Simplification of
renewal and supporting continuous participation in ADAP
could be expected to reduce the risk of lapses in HIV treatment.
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